Last reviewed · How we verify
NCT05932550: MRV-PSD
Safety of Maraviroc for Post-stroke Depression
Phase 2 trial testing Maraviroc 300 mg in Post-stroke Depression in 10 participants. Completed in 4 August 2022.
4 August 2022
Quick facts
| Lead sponsor | Tel-Aviv Sourasky Medical Center |
|---|---|
| Phase | Phase 2 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 10 |
| Start date | 4 August 2020 |
| Primary completion | 4 August 2022 |
| Estimated completion | 4 August 2022 |
| Sites | 1 location across Israel |
Drugs / interventions tested
- Maraviroc 300 mg — full drug profile →
Conditions studied
- Post-stroke Depression — all drugs for Post-stroke Depression →
Sponsor
Tel-Aviv Sourasky Medical Center
Who can join
Adults 50 to 86, any sex, with Post-stroke Depression. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Post-stroke depression (PSD) is a barrier to effective rehabilitation and recovery after stroke. Current treatment options are limited and there is an unmet need for specific and effective therapeutic options. Objective: To examine the safety and efficacy of Maraviroc, a CCR5 antagonist, as a possible add-on treatment option for PSD, in an open-labeled proof-of-concept clinical trial. Design, Setting, and Participants: A 10-week trial of daily oral 300 mg Maraviroc in ten patients with subcortical stroke suffering from PSD. Follow-up: eight weeks after completing treatment. Main Outcome Measure: A change in the Montgomery-Asberg Depression Rating Scale (MADRS).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Blocking CCR5 activity by maraviroc augmentation in post-stroke depression: a proof-of-concept clinical trial.
Tene O, Molad J, Rotschild O, Alpernas A, et al · · 2024 · cited 3× · PMID 38844862 · DOI 10.1186/s12883-024-03683-3
Verify or expand the search:
- PubMed search for NCT05932550
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Maraviroc 300 mg
Trials testing the same drug.
- NCT04441385 — Study to Evaluate the Efficacy and Safety of Maraviroc in SARS-CoV-2 Infection (COVID-19). · Phase 2 · terminated
- NCT03172026 — Maraviroc to Augment Rehabilitation Outcomes After Stroke · Phase 2, PHASE3 · terminated
- NCT03402815 — Efficacy of Maraviroc in Modulating Atherosclerosis in HIV Patients. · Phase 4 · completed
Other recruiting trials for Post-stroke Depression
Currently open trials in the same condition.
- NCT07294274 — Construction and Clinical Validation Study of a Prediction Model for Depression After Ischemic Stroke · recruiting
- NCT06598670 — Transcranial Direct Current Stimulation on Post Stroke Depression · NA · recruiting
Other Tel-Aviv Sourasky Medical Center trials
Trials by the same sponsor.
- NCT07380737 — Feasibility and Preliminary Effects of the Walking Tall App for Home-Based Gait Training in Parkinson's Disease: A Pilot · NA · recruiting
- NCT07104136 — Improving Adherence to COPD Treatments in Primary Care · NA · enrolling by invitation
- NCT07327021 — MRI-Guided Neoadjuvant Treatment De-Escalation in Stage II-III TNBC · Phase 2 · recruiting
- NCT07191249 — A Phase 2, Multicenter, Open-Label Trial to Evaluate Efficacy and Safety of Subcutaneous (SC) Mosunetuzumab in Previousl · Phase 2 · not yet recruiting
- NCT07235332 — Assessing Toxic Metal Exposure From Vegetarian/Vegan, Omnivorous, and Low-carb Diets in Israel. · enrolling by invitation
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05932550 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tel-Aviv Sourasky Medical Center
- Last refreshed: 6 July 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05932550.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing